Conference Proceedings

Relationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (Pembro) plus chemotherapy (Chemo) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): phase Ib KEYNOTE-173 trial

S Loi, P Schmid, J Cortes, YH ark, E Munoz-Couselo, S-B Kim, J Sohn, S-A Im, E Holgado, T Foukakis, S Kuemmel, R Dent, A Wang, G Aktan, V Karantza, R Salgado

CANCER RESEARCH | AMER ASSOC CANCER RESEARCH | Published : 2019